October closed with several excellent publications of Chapman Pharmacists concluding their research findings.

Global Cancer Statistics 2022: The Trends Projection Analysis

Dr. Keykavous Parang published in the Chemical Biology Letters on the life-saving practice of the theranostic approach to cancer treatments. Medical practitioners utilization of both a therapeutical development approach as well as diagnostic treatments may provide higher life expectancy for cancer patients across the world, regardless of type of cancers. Dr. Parang uses lung cancer, the deadliest cancer, as a model for how theranostic treatments would lessen the mortality rates by by developing preventative measures across the world, regardless of a regions socio-economic status.  New advances in science will continue to revolutionize the drug delivery options for cancer patients and further support practitioner’s comprehension of pathophysiology and lessen the death-rate of all cancers across the world, especially as health systems design their facilities to support theranostics. You can find the full paper here.

The U.S. Travel Health Pharmacists’ Role in a Post-COVID-19 Pandemic Era

Dr. Karl Hess contributed to recommendations on how community pharmacists can adapt their practices to meet their region’s specific travel entry-requirements as the world continues to lessen general safety measures put in place for COVID-19. As the demand for international travel opportunities rise for both business and leisure, pharmacists play a dominating role in ensuring that up-to-date “stop the spread” measures are enforced. Primarily, continuing to offer tele-health appointments, continuing to practice COVID-19 prevention measures, recommending patients remain on top of routine vaccines, and encouraging evidence-based information are the top actions pharmacists can do to ensure the safe travels to their patients as border continue to open for visitors. You can find the full paper here.

Efficacy and Safety of a Brain-Penetrant Biologic TNF-α Inhibitor in Aged APP/PS1 Mice

Post-doctoral researcher Joshua Yang was the lead author in conceptualization, data creation, funding acquisition, and supervision, and worked alongside several Chapman Pharmacy post-doctoral researchers (Weijun Ou, Devaraj Chandrashekar, Tamara Abdullah, Jiahong Sun, Chuli Roules, and Nataraj Jagadeesan) and faculty Dr. Rachita K. Sumbria in research that found TNF-α inhibitor, a brain-penetrant, had greater therapeutic successes than etanercept, a non-brain-penetrant structured analog in treatments for brains with Alzheimer’s Disease. You can find the full paper here.